Status:
UNKNOWN
Cyclophosphamide Versus Methotrexate for Remission Maintenance in Systemic Necrotizing Vasculitides
Lead Sponsor:
University of Parma
Conditions:
Wegener's Granulomatosis
Churg-Strauss Syndrome
Eligibility:
All Genders
18-80 years
Phase:
PHASE2
Brief Summary
The Systemic Necrotizing Vasculitides (SNV) encompass a group of rare diseases which include Wegener's Granulomatosis (WG), Churg-Strauss Syndrome (CSS), Microscopic polyangiitis (MPA)and Polyarteriti...
Eligibility Criteria
Inclusion
- Diagnosis of clinically active SNV
- Life-expectancy \> 1 year
- Written informed consent
Exclusion
- Creatinine clearance \< 10 ml/min/1.73 mq
- Aminotransferase levels more than twice the upper limit of the normal range
- HBsAg positivity
- anti-HCV Ig and HCV-RNA positivity
- HIV positivity
- Active malignancies
- Coexistence of connective tissue disease
- Prednisolone, cyclophosphamide or methotrexate hypersensitivity
- Pregnancy
Key Trial Info
Start Date :
Trial Type :
INTERVENTIONAL
End Date :
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00751517
Last Update
September 12 2008
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Clinical Medicine Nephrology and Health Science, Parma University Hospital
Parma, Italy/Parma, Italy, 43100